Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

免疫原性二价（发动机）病毒学接种疫苗佐剂增强剂量中期分析医学耐受性疫苗试验不利影响临床试验抗体免疫学化学内科学免疫系统效价有机化学金属

作者

Chijioke Bennett,Wayne Woo,Mark Bloch,Kan Luk Cheung,Paul Griffin,Ram Mohan,Sachin Kumar Deshmukh,Manit Arya,Oscar Cumming,A. Munro Neville,Toni G. McCallum Pardey,Joyce S. Plested,Shane Cloney-Clark,Mingzhu Zhu,Raj Kalkeri,Nita Patel,Alex Marcheschi,Jennifer L. Swan,Gale Smith,Iksung Cho,Gregory M. Glenn,Robert Walker,Raburn M. Mallory,Anna Anderson,Mary Jasmin Ang,Timothy Barnes,Michelle Bassin,Kate Bessey,Simon Bowler,Sheetal Bull,Lucy Burr,Robert Burton,Michelle L. Byrne,Robert J. Carroll,Nina Chee,A. Y. O. Choy,Malcolm Clark,Marije Dalebout,Peter De Wet,Kshama Deshmukh,Sergio Diez Alvarez,Dominic Douglas,Jacqueline Engelander,Carla Evangelista,Stuart Game,Nigel Glass,Elizabeth Gunner,Jennifer Han,Michael Harrison,Jason Doong Hing Kiang,Thazin Hlaing,Divyansh Joshi,Sean Joyce,Karen Kaluhin,Milanka Kavic,Juliana Kononov,Gary Lee,Wei‐I Lee,Indika Leelasena,Elvynna Leong,In Seok Lim,Graham Lister,Declan Loh,Mary Magdy,Callum Maggs,Amith Mammoottil,Shannon McCarthy,Nicole McKay,M. Melek,Adrian Michael Barnett,Ram Mohan,Andrew Moore,Amanda L. Moore,Louise Murdoch,Fiona Napier-Flood,Ushma Narsai,Alexander Neville,Paul Nguyen,Ekaterina Odarchenko,Toni McCallum Pardey,Dick Quan,Ushank Ranagsinghe,Roy Rasalam,Shiva Rayar,Gonasagaran Jay Ruthnam,Pi Seet,Deon Smith,Krishna Srilakshmanan,Angela Taggart,Florence Tiong,B H Toh,Eniko Ujvary,Stephanie E Wallace,Rebecca B. Wolf,Ian Chi Kei Wong,Hye Jin Yoo,Rhys Young

出处

期刊：Lancet Infectious Diseases [Elsevier]
日期：2024-03-01 被引量：1

链接

thelancet.com nih.govdoi.org

标识

DOI：10.1016/s1473-3099(24)00077-x

摘要

SARS-CoV-2 variants evade immunity despite vaccination with prototype COVID-19 vaccines or previous infection. The 2019nCoV-311 (part 2) study is evaluating immune responses after two booster doses of a vaccine containing the omicron BA.5 subvariant spike protein in adults previously vaccinated with a prototype mRNA vaccine. This interim analysis reports on day 28 immunogenicity and safety outcomes after one booster dose.

求助该文献

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

今日热心研友